title: Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence.
abstract: Hepatitis C virus (HCV) infection has become the most common indication for liver transplantation in the United States and Europe. Recurrence of HCV is universal in all liver graft recipients, but the natural history of the disease is variable with some patients displaying slowly progressive liver injury, while approximately 30% become cirrhotic within five yr of surgery. Currently, liver biopsy is the reference standard to assess liver injury in the post-transplant setting. But biopsy is associated with complications such as bleeding and pain, as well as the risk of sampling error and discordance in reporting between histopathologists. Thus, as in the pre-transplant setting, there is increasing attention being drawn to the use of non-invasive tests of liver fibrosis. This review examines the role of non-invasive assessment of hepatic fibrosis in the post-transplant setting including simple tests such as aspartate aminotransferase-to-platelet ratio index, the Benlloch formula, London Transplant Centre score, and finally transient elastography. The authors assess the respective advantages and disadvantages of the tests and consider how non-invasive tests of liver fibrosis can be utilized in the future management of post-transplant HCV infection.
authors.affiliation: The Southwest Liver Unit, Derriford Hospital, Plymouth, UK. tim.cross@phnt.swest.nhs.uk
authors.forename: Timothy
authors.initials: T
authors.lastname: J S Cross
authors.forename: Dinesh
authors.initials: D
authors.lastname: Jothimani
authors.forename: Michael A
authors.initials: MA
authors.lastname: Heneghan
authors.forename: Phillip M
authors.initials: PM
authors.lastname: Harrison
mesh_terms: D016174:Hepacivirus / Q000472:pathogenicity*; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology*; D016031:Liver Transplantation / Q000009:adverse effects*; D012008:Recurrence; D012307:Risk Factors